AndreyPopov Shares of pharmaceutical company, Aquestive Therapeutics (NASDAQ:AQST) jumped 137.29% (YoY) after the Food and Drug Administration (FDA) approved rival company ARS Pharmaceuticals' (SPRY) "epinephrine nasal spray" also called Neffy. This drug is the first nasal spray to be authorized for emergency allergic reactions (anaphylaxis) giving a substitute to auto-injectors known as EpiPens. In this article, I will explain why this is the right time to buy AQST stock due to the company's robust res ...

Aquestive Therapeutics Inc. (NASDAQ:AQST) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bennett Watson - ICR Westwicke Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Officer Carl Kraus - Chief Medical Officer Stephen Wargacki - Chief Science Officer Sherry Korczynski - Senior Vice President of Sales and Marketing Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler François Brisebois - Oppenheimer R ...

For the quarter ended June 2024, Aquestive Therapeutics (AQST) reported revenue of $20.1 million, up 51.8% over the same period last year. EPS came in at -$0.03, compared to -$0.10 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $12.62 million, representing a surprise of +59.31%. The company delivered an EPS surprise of +72.73%, with the consensus EPS estimate being -$0.11.While investors scrutinize revenue and earnings changes year-over-year and how they compare wit ...

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 72.73%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.09 per share when it actually produced a loss of $0.17, delivering a surprise of -88.89%.Over the last four q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commissi ...

Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDA • Expanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distribution anticipated in the fourth quarter 2024 • Anticipates holding epinephrine prodrug technology investor day in the ...

Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDAExpanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distribution anticipated in the fourth quarter 2024Anticipates holding epinephrine prodrug technology investor day in the coming monthsFinishes the second quarter 2024 with cash and cash equivalents of approximately $90 million and reaffirm ...

WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2024 and provide an update on recent developments in its business after market close on Tuesday, August 6, 2024. Management will host a conference call for i ...

WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2024 and provide an update on recent developments in its business after market close on Tuesday, August 6, 2024. Management will host a conference call for ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Aquestive Therapeutics, Inc. (AQST) is a pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 16.7% downward over the last 60 days.Central Garden & Pet Company (CENTA) is a consumer goods company. The Zacks Consensus Estimate for its current year earnings has been revised 5% downward over the last 60 days.LiveRamp Holdings, Inc. (RAMP) is a technology company.The Zacks Consensus Estimate ...